Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 2/20 | 0.74 |
| ▸ | TERT | O14746 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.44 |
| ▸ | FDPS | P14324 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.39 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.39 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.39 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30620153 | 1.00 | TBXAS1 (0.74) | TBXAS1TERTCHRM1TAAR1FDPS | |
| Hydrochloric Acid SCHEMBL28313785 | 0.98 | TBXAS1 (0.72) | TBXAS1TERTCHRM1TAAR1FDPS | |
| Hydrochloric Acid SCHEMBL11095352 | 0.98 | TBXAS1 (0.75) | TBXAS1TERTCHRM1TAAR1FDPS | |
| Hydrochloric Acid SCHEMBL8937731 | 0.98 | TBXAS1 (0.75) | TBXAS1TERTCHRM1TAAR1FDPS | |
| Bromide SCHEMBL28875643 | 0.98 | TBXAS1 (0.72) | TBXAS1TERTCHRM1TAAR1FDPS | |
| Sulfuric Acid SCHEMBL28313783 | 0.93 | TBXAS1 (0.66) | TBXAS1TERTCHRM1TAAR1FDPS | |
| SCHEMBL8979265 | 0.89 | TBXAS1 (0.87) | TBXAS1TERTTAAR1FDPSALOX15 | |
| Hydrochloric Acid SCHEMBL11657876 | 0.87 | TBXAS1 (0.87) | TBXAS1TERTTAAR1FDPSALOX15 | |
| SCHEMBL4655987 | 0.87 | TBXAS1 (0.97) | TBXAS1TERTTAAR1FDPS | |
| SCHEMBL7051672 | 0.85 | TBXAS1 (1.00) | TBXAS1TERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 451 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121528553-B | Sepsis myocardial function prognosis prediction method based on imidazole propionic acid targeted intervention | Zhoupu Hospital, Pudong New Area, Shanghai (Zhoupu Hospital Affiliated to Shanghai Medical College) (CN) | 2026-05-26 | — | — | CN | claimed |
| US-20260000770-A1 | LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USES THEREOF | BEIJING QL BIOPHARMACEUTICAL CO LTD (CN) | 2026-01-01 | — | — | US | claimed |
| WO-2025226506-A1 | MONO- AND DUAL-AGONIST COMPOUNDS OF HUMAN GLP1R AND GIPR FOR OBESITY & T2DM | PROTAGONIST THERAPEUTICS, INC. (US) | 2025-10-30 | — | — | WO | claimed |
| US-20250276068-A1 | PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USES THEREOF | BEIJING QL BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-09-04 | — | — | US | claimed |
| US-20240424011-A1 | COMBINATION THERAPY OF HYPOXIA-RESPONSIVE PRODRUG OF AN ANTICANCER DRUG AND RADIOTHERAPY, AND NOVEL HYPOXIA-RESPONSIVE PRODRUG | UNIVERSITY OF TSUKUBA (JP) | 2024-12-26 | — | — | US | claimed |
| EP-4454646-A1 | COMBINATION THERAPY INVOLVING RADIOTHERAPY AND HYPOXIA-RESPONSIVE PRODRUG OF ANTICANCER DRUG, AND NOVEL HYPOXIA-RESPONSIVE PRODRUG | University of Tsukuba (JP) | 2024-10-30 | — | — | EP | claimed |
| CN-118184679-A | Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material | 中国石油天然气股份有限公司 | 2024-06-14 | — | — | CN | claimed |
| US-20240181016-A1 | POLYPEPTIDE CONJUGATES AND METHODS OF USES | BEIJING QL BIOPHARMACEUTICAL CO., LTD. (CN) | 2024-06-06 | — | — | US | claimed |
| EP-4337244-A1 | PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USES THEREOF | Beijing QL Biopharmaceutical Co., Ltd. (CN) | 2024-03-20 | — | — | EP | claimed |
| CN-117598247-A | Application of imidazole propionic acid in preparation of modeling agent for inducing ulcerative colitis animal model | 天津中医药大学 | 2024-02-27 | — | — | CN | claimed |
| WO-2009137291-A2 | SPIROAZAINDOLES | MERCK & CO., INC. (US) | 2009-11-12 | — | — | WO | claimed |
| JP-3759748-B2 | — | — | 2006-03-29 | — | — | JP | claimed |
| CN-1085980-C | Meta-guanidino, ureido, thioureido or azacyclic aminobenzoic acid derivatives as integrin antagonists | SEARLE & CO (US) | 2002-06-05 | — | — | CN | claimed |
| EP-0736038-B1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK AS (DK) | 2001-07-04 | — | — | EP | claimed |
| CN-1052730-C | Compounds with growth hormone releasing properties | NOVO NORDISK AS (DK) | 2000-05-24 | — | — | CN | claimed |
| US-5854211-A | Compounds with growth hormone releasing properties | NOVO NORDISK A/S (DK) | 1998-12-29 | — | — | US | claimed |
| CN-1138334-A | Compounds with growth hormone releasing properties | NOVO NORDISK AS (DK) | 1996-12-18 | — | — | CN | claimed |
| EP-0736038-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1996-10-09 | — | — | EP | claimed |
| EP-0604368-B1 | Anti retroviral hydrazine derivatives | CIBA GEIGY AG (CH) | 1996-09-18 | — | — | EP | claimed |
| WO-1995017422-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1995-06-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240181016-A1 | POLYPEPTIDE CONJUGATES AND METHODS OF USES | GLP1R, GIPR, IAPP | TBXAS1 2422/4885TERT 3965/4885CHRM1 2407/4885 |
| US-20250276068-A1 | PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USES THEREOF | GLP1R, GIPR, IAPP | TBXAS1 1782/4885TERT 4220/4885CHRM1 2062/4885 |
| US-20240424011-A1 | COMBINATION THERAPY OF HYPOXIA-RESPONSIVE PRODRUG OF AN ANTICANCER DRUG AND RADIOTHERAPY, AND NOVEL HYPOXIA-RESPONSIVE PRODRUG | HIF1AN, HIF1A, PAICS | TBXAS1 1408/4885TERT 419/4885CHRM1 4736/4885 |
| US-20260000770-A1 | LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USES THEREOF | GLP1R, GIPR, VIP | TBXAS1 1548/4885TERT 4464/4885CHRM1 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.